Stelexis Therapeutics
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
780 3rd Ave Fl 37 Th, New York City, New...Phone Number
(212) 692-7178Website
www.stelexis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About Stelexis Therapeutics
Stelexis BioSciences is a clinical-stage biopharmaceutical company focused on developing novel treatments to eradicate hematological cancers at their root causes. The company addresses significant unmet medical needs in hematological malignancies, including acute myeloid leukemia and myelodysplastic syndromes. Their pipeline aims to induce remissions, prevent relapse, and improve patient outcomes and survival rates. Stelexis BioSciences is dedicated to advancing innovative therapies for patients suffering from these complex conditions.Explore more
Stelexis Therapeutics Org Chart
RA
Vice President, Head of CMC
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Stelexis Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Stelexis Therapeutics has new funding data
Check out if Stelexis Therapeutics is spiking on competitors!
Product Launch: Get notified when Stelexis Therapeutics launches new products
Check if Stelexis Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Stelexis Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Stelexis Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Stelexis Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Stelexis Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Stelexis Therapeutics
Compare insights from companies similar to Stelexis Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Stelexis Therapeutics
<$5M
1-10
Private
$43M
2017
MP
Marie PaytonSenior VP, Clinical Development Operations
Company Profile Activity
Activity Insights
Stelexis Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Stelexis Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Stelexis Therapeutics.
Stelexis Therapeutics financials insights
Gather financial insights about Stelexis Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$43M
Stelexis Therapeutics Tech Stack
A closer look at the technologies used by Stelexis Therapeutics
See more technologies
Stelexis Therapeutics News & Media
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Stelexis Therapeutics
Sign Up For FreeTo access detailed company insights
Stelexis BioSciences is a clinical-stage biopharmaceutical company focused on developing novel treatments to eradicate hematological cancers at their root causes. The company addresses significant unmet medical needs in hematological malignancies, including acute myeloid leukemia and myelodysplastic syndromes. Their pipeline aims to induce remissio... Read More
